Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors with Sonoma Biotherapeutics’ pioneering approach to developing and manufacturing gene-modified Treg cell therapies.

Latham & Watkins LLP advised Sonoma Biotherapeutics in the transaction with licensing deal team led by Bay Area partner Judith Hasko, with associates Robert Yeh, Kristina Funahashi and Xiaohan Wu, and a corporate deal team led by Mark Roeder, with associate Michelle Chern. Advice was also provided on tax matters by partner Kirt Switzer; and on data privacy matters by partner Heather Deixler.